News UK's Trogenix raises £70m for cancer immunotherapy platform Edinburgh-based Trogenix has raised £70m to fund clinical trials of its triple-acting immunotherapies for brain and colorectal cancers.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.